BMO Capital analyst Etzer Darout initiated coverage of Tourmaline Bio (TRML) with an Outperform rating and $50 price target The company’s initial product candidate, TOUR006, is a “potentially best-in-class” long-acting antibody, according to the analyst, who believes important de-risking data for TOUR006 in TED and atherosclerosis in 2025 “represent meaningful upside” from current levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML: